Gelesia Pharmaceuticals - B (01672): The compound formulation of once-monthly new generation pancreatic amylin receptor agonist ASC36 and once-monthly new generation GLP-1R/GIPR dual-target agonist ASC35 entered the clinical development stage.

Zhixin Finance APP News, GL Pharm-B (01672) announced that once monthly new generation amylin receptor agonist ASC36 and once monthly new generation GLP-1R/GIPR dual target agonist ASC35 compound formulations have entered the clinical development stage. GL Pharm expects to submit an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) in the second quarter of 2026 for ASC36 and ASC35 compound formulations for the treatment of obesity.